{"id":353169,"date":"2025-08-28T08:01:18","date_gmt":"2025-08-28T08:01:18","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-united-therapeutics-corporation\/"},"modified":"2025-08-28T08:01:18","modified_gmt":"2025-08-28T08:01:18","slug":"how-to-buy-united-therapeutics-corporation","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","title":{"rendered":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334018,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-353169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"2025 f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile United Therapeutics Corporation (UTHR) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"2025 f\u0131rsatlar\u0131 i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile United Therapeutics Corporation (UTHR) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"Hayat kurtaran ve ayn\u0131 zamanda servetinizi b\u00fcy\u00fctme potansiyeline sahip bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? United Therapeutics Corporation, ileri biyoteknolojiyi sa\u011flam finansal performansla birle\u015ftiriyor. Bu sadece ba\u015fka bir ila\u00e7 hissesi de\u011fil\u2014organ \u00fcretiminde \u00f6nc\u00fc ve pulmoner hastal\u0131k tedavisini d\u00f6n\u00fc\u015ft\u00fcren bir \u015firket. UTHR'nin neden dikkatinizi hak etti\u011fini ve t\u0131bbi devrimlerinin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Hayat kurtaran ve ayn\u0131 zamanda servetinizi b\u00fcy\u00fctme potansiyeline sahip bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? United Therapeutics Corporation, ileri biyoteknolojiyi sa\u011flam finansal performansla birle\u015ftiriyor. Bu sadece ba\u015fka bir ila\u00e7 hissesi de\u011fil\u2014organ \u00fcretiminde \u00f6nc\u00fc ve pulmoner hastal\u0131k tedavisini d\u00f6n\u00fc\u015ft\u00fcren bir \u015firket. UTHR'nin neden dikkatinizi hak etti\u011fini ve t\u0131bbi devrimlerinin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 United Therapeutics Hisse Senedi Analizi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2> <p>28 A\u011fustos 2025 itibar\u0131yla United Therapeutics Corporation (UTHR) <strong>305,35 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu, yat\u0131r\u0131mc\u0131lar i\u00e7in hem f\u0131rsat hem de dikkat gerektiren kritik bir seviye. Ancak takviminize not edin: <strong>Eyl\u00fcl 2025, bu hisse i\u00e7in her \u015feyi de\u011fi\u015ftirebilecek ay<\/strong>.<\/p> <p>\u0130diopatik pulmoner fibrozis (IPF) i\u00e7in nebulize treprostinil \u00fczerine yap\u0131lacak TETON 2 klinik deneme sonu\u00e7lar\u0131 potansiyel bir d\u00f6n\u00fcm noktas\u0131d\u0131r. <a href=\"https:\/\/finimize.com\/content\/united-therapeutics-puts-big-bets-on-tyvasos-trial-results\">Finimize<\/a> analistleri olumlu sonu\u00e7lar\u0131n hisseyi \u00f6nemli \u00f6l\u00e7\u00fcde y\u00fckseltebilece\u011fini \u00f6ne s\u00fcrerken, <a href=\"https:\/\/www.ainvest.com\/news\/united-therapeutics-september-ipf-data-readout-strategic-catalyst-shareholder-2508\/\">AI Invest<\/a> bunu \"hissedar de\u011feri i\u00e7in stratejik bir kataliz\u00f6r\" olarak nitelendiriyor.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><th>Analiz<\/th><\/tr> <\/thead> <tbody> <tr><td>30 Temmuz 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>312,00 $<\/td><td>-%2,1 (EPS tahminleri ka\u00e7\u0131r\u0131ld\u0131)<\/td><td>Gelir art\u0131\u015f\u0131 ancak EPS hayal k\u0131r\u0131kl\u0131\u011f\u0131<\/td><\/tr> <tr><td>30 Nisan 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>298,50 $<\/td><td>+%4,5 (tahminleri a\u015ft\u0131)<\/td><td>G\u00fc\u00e7l\u00fc \u00fcr\u00fcn performans\u0131<\/td><\/tr> <tr><td>26 \u015eubat 2025<\/td><td>2024 4. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>290,75 $<\/td><td>+%3,2 (sa\u011flam sonu\u00e7lar)<\/td><td>\u0130stikrarl\u0131 b\u00fcy\u00fcme modeli<\/td><\/tr> <tr><td>29 Ekim 2024<\/td><td>2024 3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>285,25 $<\/td><td>+%1,9 (beklentileri kar\u015f\u0131lad\u0131)<\/td><td>\u0130stikrarl\u0131 performans<\/td><\/tr> <\/tbody> <\/table> <p>Model, UTHR'nin genellikle kazan\u00e7lar etraf\u0131nda %2-5 hareket ya\u015fad\u0131\u011f\u0131n\u0131 g\u00f6steriyor, ancak Eyl\u00fcl TETON 2 sonu\u00e7lar\u0131 tarihsel biyoteknoloji kataliz\u00f6r olaylar\u0131na dayanarak \u00e7ok daha b\u00fcy\u00fck %15-25 dalgalanma tetikleyebilir.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2> <p>United Therapeutics son alt\u0131 ayda dalgal\u0131 ama nihayetinde olumlu bir seyir izledi:<\/p> <p><strong>\u015eubat 2025<\/strong>: 290,75 $ - G\u00fc\u00e7l\u00fc 4. \u00e7eyrek sonu\u00e7lar\u0131 temel sa\u011flad\u0131<br\/> <strong>Mart 2025<\/strong>: 302,40 $ - 1. \u00e7eyrek kazan\u00e7 beklentisi<br\/> <strong>Nisan 2025<\/strong>: 312,00 $ - Kazan\u00e7 sonras\u0131 art\u0131\u015f<br\/> <strong>May\u0131s 2025<\/strong>: 308,25 $ - Kar realizasyonu ve konsolidasyon<br\/> <strong>Haziran 2025<\/strong>: 315,50 $ - Yaz kataliz\u00f6rlerine do\u011fru momentum art\u0131\u015f\u0131<br\/> <strong>Temmuz 2025<\/strong>: 305,00 $ - 2. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131<br\/> <strong>A\u011fustos 2025<\/strong>: 305,35 $ - Mevcut stabilizasyon<\/p> <p>Bu, sekt\u00f6r i\u00e7in zorlu bir d\u00f6nemde bir\u00e7ok biyoteknoloji rakibinden \u00f6nemli \u00f6l\u00e7\u00fcde daha iyi performans g\u00f6stererek yakla\u015f\u0131k <strong>%5 b\u00fcy\u00fcme<\/strong> anlam\u0131na geliyor. Hisse, 2. \u00e7eyrek EPS tahminlerini ka\u00e7\u0131rmas\u0131na ra\u011fmen temel i\u015finde dayan\u0131kl\u0131l\u0131k g\u00f6sterdi.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist projeksiyonlar\u0131 ve \u015firket temellerine dayanarak beklenenler:<\/p> <p><strong>2025 Y\u0131l Sonu<\/strong>: 340-360 $ (y\u00fczde 20 y\u00fckseli\u015f potansiyeli) \u2192 <strong>AL<\/strong><br\/> Eyl\u00fcl TETON 2 kataliz\u00f6r\u00fc anl\u0131k kazan\u00e7lar\u0131 tetikleyebilir, 3. ve 4. \u00e7eyrek kazan\u00e7lar\u0131 momentum olu\u015fturmal\u0131.<\/p> <p><strong>2026 Tahmini<\/strong>: 380-420 $<br\/> Ba\u015far\u0131l\u0131 IPF pazar giri\u015fi ve mevcut pulmoner franchise'dan organik b\u00fcy\u00fcme devam edecek.<\/p> <p><strong>2028 Projeksiyonu<\/strong>: 500-600 $<br\/> Organ \u00fcretim teknolojileri gelirlerde anlaml\u0131 katk\u0131 sa\u011flamaya ba\u015flayacak.<\/p> <p><strong>2030 Vizyonu<\/strong>: 700-800 $+<br\/> Ksenotransplantasyon ve biyoyaz\u0131c\u0131 organlar nakil t\u0131bb\u0131n\u0131 devrim niteli\u011finde de\u011fi\u015ftirebilir.<\/p> <p><a href=\"https:\/\/stockanalysis.com\/stocks\/uthr\/forecast\/\">StockAnalysis<\/a> analistleri, ortalama fiyat hedefleri yakla\u015f\u0131k 382 $ olan \"Al\" tavsiyesinde birle\u015fiyor, bu da mevcut seviyelerden \u00f6nemli bir y\u00fckseli\u015f potansiyeli anlam\u0131na geliyor.<\/p> <h2>\u26a0\ufe0f Yat\u0131r\u0131m Riskleri: Neler Yanl\u0131\u015f Gidebilir<\/h2> <h3>Reg\u00fclasyon ve Klinik Riskler<\/h3> <p>TETON 2 denemesinin ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 y\u0131k\u0131c\u0131 olur\u2014hisseyi an\u0131nda %30-40 d\u00fc\u015f\u00fcrebilir. Biyoteknoloji sekt\u00f6r\u00fc yo\u011fun reg\u00fclasyon bask\u0131s\u0131 alt\u0131nda ve FDA'dan gelebilecek gecikmeler veya reddedilmeler zaman \u00e7izelgelerini ve gelir projeksiyonlar\u0131n\u0131 ciddi \u015fekilde etkileyebilir.<\/p> <h3>Rekabet Bask\u0131lar\u0131<\/h3> <p>United Therapeutics, daha b\u00fcy\u00fck finansal kaynaklara sahip \u015firketlerden artan rekabetle kar\u015f\u0131 kar\u015f\u0131ya. Jenerik rakiplerin ortaya \u00e7\u0131kmas\u0131, \u00f6zellikle patentlerin sona ermesiyle mevcut \u00fcr\u00fcnlerin fiyatlama g\u00fcc\u00fcn\u00fc tehdit ediyor.<\/p> <h3>Mali Zay\u0131fl\u0131klar<\/h3> <p>G\u00fc\u00e7l\u00fc nakit ak\u0131\u015f\u0131na ra\u011fmen, i\u015fletme giderleri son raporlara g\u00f6re 321,4 milyon dolardan 411,6 milyon dolara keskin \u015fekilde y\u00fckseldi. Bu gider art\u0131\u015f\u0131, gelir art\u0131\u015f\u0131yla dengelenmezse marjlar \u00fczerinde bask\u0131 olu\u015fturabilir.<\/p> <h2>\ud83d\ude80 Olumlu \u0130\u015faretler: Neden UTHR Y\u00fckselebilir<\/h2> <h3>Anl\u0131k Kataliz\u00f6rler<\/h3> <p>Eyl\u00fcl 2025 TETON 2 sonu\u00e7lar\u0131 potansiyel bir piyasa yeniden tan\u0131mlama an\u0131n\u0131 temsil ediyor. Olumlu veriler, United Therapeutics'in \u00f6nemli \u00f6l\u00e7\u00fcde yakalayabilece\u011fi 7,15 milyar dolarl\u0131k IPF tedavi pazar\u0131n\u0131 a\u00e7abilir.<\/p> <h3>G\u00fc\u00e7l\u00fc Finansal Temel<\/h3> <p>1,2 milyar dolar i\u015fletme nakit ak\u0131\u015f\u0131 ve 1 milyar dolarl\u0131k hisse geri al\u0131m program\u0131 ile \u015firket, volatiliteyi a\u015fmak ve hissedarlara de\u011fer d\u00f6nd\u00fcrmek i\u00e7in \u00f6nemli kaynaklara sahip.<\/p> <h3>\u0130novasyon Hatt\u0131<\/h3> <p>Geleneksel ila\u00e7lar\u0131n \u00f6tesinde, United Therapeutics, nakil t\u0131bb\u0131n\u0131 temelden d\u00f6n\u00fc\u015ft\u00fcrebilecek organ \u00fcretim teknolojilerinde \u00f6nc\u00fcl\u00fck ediyor\u2014potansiyel olarak milyarlarca dolarl\u0131k bir pazar.<\/p> <h3>Kurumsal G\u00fcven<\/h3> <p>Vanguard Group gibi b\u00fcy\u00fck yat\u0131r\u0131mc\u0131lar pozisyonlar\u0131n\u0131 art\u0131r\u0131yor, bu da profesyonel para y\u00f6neticilerinin \u015firketin uzun vadeli beklentilerine olan g\u00fcvenini yans\u0131t\u0131yor.<\/p> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>Eyl\u00fcl Kataliz\u00f6r\u00fcn\u00fc Bekleyin<\/strong>: TETON 2 sonu\u00e7lar\u0131 netlik sa\u011flayacak\u2014veri a\u00e7\u0131klamas\u0131ndan sonra sonu\u00e7 ne olursa olsun pozisyon a\u00e7may\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Ortalama Maliyetle Al\u0131m Yap\u0131n<\/strong>: Eyl\u00fclden \u00f6nce al\u0131m yap\u0131yorsan\u0131z, zamanlama riskini azaltmak i\u00e7in k\u00fc\u00e7\u00fck kademeli al\u0131mlar kullan\u0131n<\/li> <li><strong>Stop-Loss Belirleyin<\/strong>: Klinik verilerin ikili do\u011fas\u0131 nedeniyle yat\u0131r\u0131m\u0131 %15-20 stop-loss emirleriyle koruyun<\/li> <li><strong>Ak\u0131ll\u0131ca Tahsis Edin<\/strong>: Sekt\u00f6r volatilitesi nedeniyle UTHR'yi toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10'unu ge\u00e7meyecek \u015fekilde s\u0131n\u0131rlay\u0131n<\/li> <\/ol> <p>Esprili deneyimli t\u00fcccar \u00f6\u011f\u00fcd\u00fc: \"Biyotek hisse senetleriyle i\u015flem yapmak ameliyat yapmak gibidir\u2014bazen sabit ellere ihtiyac\u0131n\u0131z vard\u0131r, bazen de i\u015fler kar\u0131\u015fmadan \u00f6nce masadan kalkmay\u0131 bilmelisiniz!\"<\/p> <h2>\u2705 United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir Ticaret Platformu Se\u00e7in<\/td><td>NASDAQ eri\u015fimi ve makul komisyon \u00fccretleri sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Kimlik belgeleri sa\u011flay\u0131n\u2014genellikle 1-2 i\u015f g\u00fcn\u00fc s\u00fcrer<\/td><\/tr> <tr><td>3<\/td><td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td><td>Banka transferi, havale veya di\u011fer mevcut y\u00f6ntemlerle para aktar\u0131n<\/td><\/tr> <tr><td>4<\/td><td>UTHR'yi \u0130yice Ara\u015ft\u0131r\u0131n<\/td><td>Yat\u0131r\u0131m yapmadan \u00f6nce \u015firketin \u00fcr\u00fcnlerini, pipeline'\u0131n\u0131 ve risklerini anlay\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Sipari\u015finizi Verin<\/td><td>Piyasa emirleri yerine giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>6<\/td><td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 \u0130zleyin<\/td><td>Fiyat uyar\u0131lar\u0131 kurun ve \u015firket haberlerini d\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td><\/tr> <tr><td>7<\/td><td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td><td>Avantajl\u0131 vergi muamelesi i\u00e7in tutma s\u00fcresi gereksinimlerini anlay\u0131n<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden \u00d6ne \u00c7\u0131k\u0131yor<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, UTHR gibi hisselere eri\u015fimi kolayla\u015ft\u0131ran birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> - Neredeyse herhangi bir miktarla ba\u015flay\u0131n, stratejileri \u00f6nemli risk olmadan test etmek i\u00e7in ideal<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama S\u00fcreci<\/strong> - Sadece bir belge ile KYC tamamlay\u0131n, genellikle g\u00fcnler yerine dakikalar i\u00e7inde onay al\u0131n<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong> - Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100'den fazla y\u00f6ntem<\/li> <li><strong>Kullan\u0131c\u0131 Dostu Platform<\/strong> - \u00d6zellikle hisse senedi yat\u0131r\u0131m\u0131na yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f sezgisel aray\u00fcz<\/li> <\/ul> <h2>\ud83c\udf0d 2025'te United Therapeutics: T\u0131bbi \u0130novasyon Lideri<\/h2> <p>United Therapeutics Corporation, ya\u015fam kurtaran pulmoner hastal\u0131k tedavileri geli\u015ftirme ve organ naklinin gelece\u011fini \u015fekillendirme odakl\u0131 biyoteknoloji inovasyonunun \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirketin mevcut piyasa konumu g\u00fc\u00e7l\u00fcd\u00fcr ve Tyvaso DPI, Remodulin, Orenitram ve Unituxin gibi hastalar\u0131n ya\u015fam kalitesini \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131ran \u00e7e\u015fitli \u00fcr\u00fcn portf\u00f6y\u00fcne sahiptir.<\/p> <p>\u015eirket, sosyal sorumluluk ile hissedar de\u011ferini birlikte g\u00fc\u00e7lendiren kamu yarar\u0131na bir \u015firket olarak faaliyet g\u00f6stermektedir. Yakla\u015f\u0131k 1.305 \u00e7al\u0131\u015fan\u0131 ve Maryland, Kuzey Carolina, Quebec, Florida, Virginia ve New Hampshire'da tesisleri ile United Therapeutics, s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcme i\u00e7in sa\u011flam bir operasyonel temel olu\u015fturmu\u015ftur.<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: United Therapeutics, ksenotransplantasyon (hayvan organlar\u0131 kullan\u0131m\u0131), allojenik resell\u00fclerizasyon ve otolog biyoyaz\u0131c\u0131 olmak \u00fczere \u00fc\u00e7 devrim niteli\u011finde teknolojiyle \u00fcretilmi\u015f organlar geli\u015ftiriyor. Temelde, hastalar\u0131n ihtiya\u00e7 duyduklar\u0131nda yedek organ sipari\u015f edebilece\u011fi d\u00fcnyan\u0131n ilk \"organ eczanesini\" yarat\u0131yorlar!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 United Therapeutics Hisse Senedi Analizi: G\u00fcncel Fiyat ve Kritik Tarihler<\/h2>\n<p>28 A\u011fustos 2025 itibar\u0131yla United Therapeutics Corporation (UTHR) <strong>305,35 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor\u2014bu, yat\u0131r\u0131mc\u0131lar i\u00e7in hem f\u0131rsat hem de dikkat gerektiren kritik bir seviye. Ancak takviminize not edin: <strong>Eyl\u00fcl 2025, bu hisse i\u00e7in her \u015feyi de\u011fi\u015ftirebilecek ay<\/strong>.<\/p>\n<p>\u0130diopatik pulmoner fibrozis (IPF) i\u00e7in nebulize treprostinil \u00fczerine yap\u0131lacak TETON 2 klinik deneme sonu\u00e7lar\u0131 potansiyel bir d\u00f6n\u00fcm noktas\u0131d\u0131r. <a href=\"https:\/\/finimize.com\/content\/united-therapeutics-puts-big-bets-on-tyvasos-trial-results\">Finimize<\/a> analistleri olumlu sonu\u00e7lar\u0131n hisseyi \u00f6nemli \u00f6l\u00e7\u00fcde y\u00fckseltebilece\u011fini \u00f6ne s\u00fcrerken, <a href=\"https:\/\/www.ainvest.com\/news\/united-therapeutics-september-ipf-data-readout-strategic-catalyst-shareholder-2508\/\">AI Invest<\/a> bunu &#8220;hissedar de\u011feri i\u00e7in stratejik bir kataliz\u00f6r&#8221; olarak nitelendiriyor.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<th>Analiz<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>30 Temmuz 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>312,00 $<\/td>\n<td>-%2,1 (EPS tahminleri ka\u00e7\u0131r\u0131ld\u0131)<\/td>\n<td>Gelir art\u0131\u015f\u0131 ancak EPS hayal k\u0131r\u0131kl\u0131\u011f\u0131<\/td>\n<\/tr>\n<tr>\n<td>30 Nisan 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>298,50 $<\/td>\n<td>+%4,5 (tahminleri a\u015ft\u0131)<\/td>\n<td>G\u00fc\u00e7l\u00fc \u00fcr\u00fcn performans\u0131<\/td>\n<\/tr>\n<tr>\n<td>26 \u015eubat 2025<\/td>\n<td>2024 4. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>290,75 $<\/td>\n<td>+%3,2 (sa\u011flam sonu\u00e7lar)<\/td>\n<td>\u0130stikrarl\u0131 b\u00fcy\u00fcme modeli<\/td>\n<\/tr>\n<tr>\n<td>29 Ekim 2024<\/td>\n<td>2024 3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>285,25 $<\/td>\n<td>+%1,9 (beklentileri kar\u015f\u0131lad\u0131)<\/td>\n<td>\u0130stikrarl\u0131 performans<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Model, UTHR&#8217;nin genellikle kazan\u00e7lar etraf\u0131nda %2-5 hareket ya\u015fad\u0131\u011f\u0131n\u0131 g\u00f6steriyor, ancak Eyl\u00fcl TETON 2 sonu\u00e7lar\u0131 tarihsel biyoteknoloji kataliz\u00f6r olaylar\u0131na dayanarak \u00e7ok daha b\u00fcy\u00fck %15-25 dalgalanma tetikleyebilir.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu ve Trend Analizi<\/h2>\n<p>United Therapeutics son alt\u0131 ayda dalgal\u0131 ama nihayetinde olumlu bir seyir izledi:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: 290,75 $ &#8211; G\u00fc\u00e7l\u00fc 4. \u00e7eyrek sonu\u00e7lar\u0131 temel sa\u011flad\u0131<br \/> <strong>Mart 2025<\/strong>: 302,40 $ &#8211; 1. \u00e7eyrek kazan\u00e7 beklentisi<br \/> <strong>Nisan 2025<\/strong>: 312,00 $ &#8211; Kazan\u00e7 sonras\u0131 art\u0131\u015f<br \/> <strong>May\u0131s 2025<\/strong>: 308,25 $ &#8211; Kar realizasyonu ve konsolidasyon<br \/> <strong>Haziran 2025<\/strong>: 315,50 $ &#8211; Yaz kataliz\u00f6rlerine do\u011fru momentum art\u0131\u015f\u0131<br \/> <strong>Temmuz 2025<\/strong>: 305,00 $ &#8211; 2. \u00e7eyrek kazan\u00e7 hayal k\u0131r\u0131kl\u0131\u011f\u0131<br \/> <strong>A\u011fustos 2025<\/strong>: 305,35 $ &#8211; Mevcut stabilizasyon<\/p>\n<p>Bu, sekt\u00f6r i\u00e7in zorlu bir d\u00f6nemde bir\u00e7ok biyoteknoloji rakibinden \u00f6nemli \u00f6l\u00e7\u00fcde daha iyi performans g\u00f6stererek yakla\u015f\u0131k <strong>%5 b\u00fcy\u00fcme<\/strong> anlam\u0131na geliyor. Hisse, 2. \u00e7eyrek EPS tahminlerini ka\u00e7\u0131rmas\u0131na ra\u011fmen temel i\u015finde dayan\u0131kl\u0131l\u0131k g\u00f6sterdi.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist projeksiyonlar\u0131 ve \u015firket temellerine dayanarak beklenenler:<\/p>\n<p><strong>2025 Y\u0131l Sonu<\/strong>: 340-360 $ (y\u00fczde 20 y\u00fckseli\u015f potansiyeli) \u2192 <strong>AL<\/strong><br \/> Eyl\u00fcl TETON 2 kataliz\u00f6r\u00fc anl\u0131k kazan\u00e7lar\u0131 tetikleyebilir, 3. ve 4. \u00e7eyrek kazan\u00e7lar\u0131 momentum olu\u015fturmal\u0131.<\/p>\n<p><strong>2026 Tahmini<\/strong>: 380-420 $<br \/> Ba\u015far\u0131l\u0131 IPF pazar giri\u015fi ve mevcut pulmoner franchise&#8217;dan organik b\u00fcy\u00fcme devam edecek.<\/p>\n<p><strong>2028 Projeksiyonu<\/strong>: 500-600 $<br \/> Organ \u00fcretim teknolojileri gelirlerde anlaml\u0131 katk\u0131 sa\u011flamaya ba\u015flayacak.<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 700-800 $+<br \/> Ksenotransplantasyon ve biyoyaz\u0131c\u0131 organlar nakil t\u0131bb\u0131n\u0131 devrim niteli\u011finde de\u011fi\u015ftirebilir.<\/p>\n<p><a href=\"https:\/\/stockanalysis.com\/stocks\/uthr\/forecast\/\">StockAnalysis<\/a> analistleri, ortalama fiyat hedefleri yakla\u015f\u0131k 382 $ olan &#8220;Al&#8221; tavsiyesinde birle\u015fiyor, bu da mevcut seviyelerden \u00f6nemli bir y\u00fckseli\u015f potansiyeli anlam\u0131na geliyor.<\/p>\n<h2>\u26a0\ufe0f Yat\u0131r\u0131m Riskleri: Neler Yanl\u0131\u015f Gidebilir<\/h2>\n<h3>Reg\u00fclasyon ve Klinik Riskler<\/h3>\n<p>TETON 2 denemesinin ba\u015far\u0131s\u0131zl\u0131\u011f\u0131 y\u0131k\u0131c\u0131 olur\u2014hisseyi an\u0131nda %30-40 d\u00fc\u015f\u00fcrebilir. Biyoteknoloji sekt\u00f6r\u00fc yo\u011fun reg\u00fclasyon bask\u0131s\u0131 alt\u0131nda ve FDA&#8217;dan gelebilecek gecikmeler veya reddedilmeler zaman \u00e7izelgelerini ve gelir projeksiyonlar\u0131n\u0131 ciddi \u015fekilde etkileyebilir.<\/p>\n<h3>Rekabet Bask\u0131lar\u0131<\/h3>\n<p>United Therapeutics, daha b\u00fcy\u00fck finansal kaynaklara sahip \u015firketlerden artan rekabetle kar\u015f\u0131 kar\u015f\u0131ya. Jenerik rakiplerin ortaya \u00e7\u0131kmas\u0131, \u00f6zellikle patentlerin sona ermesiyle mevcut \u00fcr\u00fcnlerin fiyatlama g\u00fcc\u00fcn\u00fc tehdit ediyor.<\/p>\n<h3>Mali Zay\u0131fl\u0131klar<\/h3>\n<p>G\u00fc\u00e7l\u00fc nakit ak\u0131\u015f\u0131na ra\u011fmen, i\u015fletme giderleri son raporlara g\u00f6re 321,4 milyon dolardan 411,6 milyon dolara keskin \u015fekilde y\u00fckseldi. Bu gider art\u0131\u015f\u0131, gelir art\u0131\u015f\u0131yla dengelenmezse marjlar \u00fczerinde bask\u0131 olu\u015fturabilir.<\/p>\n<h2>\ud83d\ude80 Olumlu \u0130\u015faretler: Neden UTHR Y\u00fckselebilir<\/h2>\n<h3>Anl\u0131k Kataliz\u00f6rler<\/h3>\n<p>Eyl\u00fcl 2025 TETON 2 sonu\u00e7lar\u0131 potansiyel bir piyasa yeniden tan\u0131mlama an\u0131n\u0131 temsil ediyor. Olumlu veriler, United Therapeutics&#8217;in \u00f6nemli \u00f6l\u00e7\u00fcde yakalayabilece\u011fi 7,15 milyar dolarl\u0131k IPF tedavi pazar\u0131n\u0131 a\u00e7abilir.<\/p>\n<h3>G\u00fc\u00e7l\u00fc Finansal Temel<\/h3>\n<p>1,2 milyar dolar i\u015fletme nakit ak\u0131\u015f\u0131 ve 1 milyar dolarl\u0131k hisse geri al\u0131m program\u0131 ile \u015firket, volatiliteyi a\u015fmak ve hissedarlara de\u011fer d\u00f6nd\u00fcrmek i\u00e7in \u00f6nemli kaynaklara sahip.<\/p>\n<h3>\u0130novasyon Hatt\u0131<\/h3>\n<p>Geleneksel ila\u00e7lar\u0131n \u00f6tesinde, United Therapeutics, nakil t\u0131bb\u0131n\u0131 temelden d\u00f6n\u00fc\u015ft\u00fcrebilecek organ \u00fcretim teknolojilerinde \u00f6nc\u00fcl\u00fck ediyor\u2014potansiyel olarak milyarlarca dolarl\u0131k bir pazar.<\/p>\n<h3>Kurumsal G\u00fcven<\/h3>\n<p>Vanguard Group gibi b\u00fcy\u00fck yat\u0131r\u0131mc\u0131lar pozisyonlar\u0131n\u0131 art\u0131r\u0131yor, bu da profesyonel para y\u00f6neticilerinin \u015firketin uzun vadeli beklentilerine olan g\u00fcvenini yans\u0131t\u0131yor.<\/p>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>Eyl\u00fcl Kataliz\u00f6r\u00fcn\u00fc Bekleyin<\/strong>: TETON 2 sonu\u00e7lar\u0131 netlik sa\u011flayacak\u2014veri a\u00e7\u0131klamas\u0131ndan sonra sonu\u00e7 ne olursa olsun pozisyon a\u00e7may\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Ortalama Maliyetle Al\u0131m Yap\u0131n<\/strong>: Eyl\u00fclden \u00f6nce al\u0131m yap\u0131yorsan\u0131z, zamanlama riskini azaltmak i\u00e7in k\u00fc\u00e7\u00fck kademeli al\u0131mlar kullan\u0131n<\/li>\n<li><strong>Stop-Loss Belirleyin<\/strong>: Klinik verilerin ikili do\u011fas\u0131 nedeniyle yat\u0131r\u0131m\u0131 %15-20 stop-loss emirleriyle koruyun<\/li>\n<li><strong>Ak\u0131ll\u0131ca Tahsis Edin<\/strong>: Sekt\u00f6r volatilitesi nedeniyle UTHR&#8217;yi toplam portf\u00f6y\u00fcn\u00fcz\u00fcn %5-10&#8217;unu ge\u00e7meyecek \u015fekilde s\u0131n\u0131rlay\u0131n<\/li>\n<\/ol>\n<p>Esprili deneyimli t\u00fcccar \u00f6\u011f\u00fcd\u00fc: &#8220;Biyotek hisse senetleriyle i\u015flem yapmak ameliyat yapmak gibidir\u2014bazen sabit ellere ihtiyac\u0131n\u0131z vard\u0131r, bazen de i\u015fler kar\u0131\u015fmadan \u00f6nce masadan kalkmay\u0131 bilmelisiniz!&#8221;<\/p>\n<h2>\u2705 United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul komisyon \u00fccretleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Kimlik belgeleri sa\u011flay\u0131n\u2014genellikle 1-2 i\u015f g\u00fcn\u00fc s\u00fcrer<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Hesab\u0131n\u0131z\u0131 Fonlay\u0131n<\/td>\n<td>Banka transferi, havale veya di\u011fer mevcut y\u00f6ntemlerle para aktar\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>UTHR&#8217;yi \u0130yice Ara\u015ft\u0131r\u0131n<\/td>\n<td>Yat\u0131r\u0131m yapmadan \u00f6nce \u015firketin \u00fcr\u00fcnlerini, pipeline&#8217;\u0131n\u0131 ve risklerini anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Sipari\u015finizi Verin<\/td>\n<td>Piyasa emirleri yerine giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 \u0130zleyin<\/td>\n<td>Fiyat uyar\u0131lar\u0131 kurun ve \u015firket haberlerini d\u00fczenli olarak g\u00f6zden ge\u00e7irin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Vergi Etkilerini D\u00fc\u015f\u00fcn\u00fcn<\/td>\n<td>Avantajl\u0131 vergi muamelesi i\u00e7in tutma s\u00fcresi gereksinimlerini anlay\u0131n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden \u00d6ne \u00c7\u0131k\u0131yor<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, UTHR gibi hisselere eri\u015fimi kolayla\u015ft\u0131ran birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Yat\u0131r\u0131m Sadece 5 $<\/strong> &#8211; Neredeyse herhangi bir miktarla ba\u015flay\u0131n, stratejileri \u00f6nemli risk olmadan test etmek i\u00e7in ideal<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama S\u00fcreci<\/strong> &#8211; Sadece bir belge ile KYC tamamlay\u0131n, genellikle g\u00fcnler yerine dakikalar i\u00e7inde onay al\u0131n<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong> &#8211; Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100&#8217;den fazla y\u00f6ntem<\/li>\n<li><strong>Kullan\u0131c\u0131 Dostu Platform<\/strong> &#8211; \u00d6zellikle hisse senedi yat\u0131r\u0131m\u0131na yeni ba\u015flayanlar i\u00e7in tasarlanm\u0131\u015f sezgisel aray\u00fcz<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te United Therapeutics: T\u0131bbi \u0130novasyon Lideri<\/h2>\n<p>United Therapeutics Corporation, ya\u015fam kurtaran pulmoner hastal\u0131k tedavileri geli\u015ftirme ve organ naklinin gelece\u011fini \u015fekillendirme odakl\u0131 biyoteknoloji inovasyonunun \u00f6n saflar\u0131nda yer al\u0131yor. \u015eirketin mevcut piyasa konumu g\u00fc\u00e7l\u00fcd\u00fcr ve Tyvaso DPI, Remodulin, Orenitram ve Unituxin gibi hastalar\u0131n ya\u015fam kalitesini \u00f6nemli \u00f6l\u00e7\u00fcde art\u0131ran \u00e7e\u015fitli \u00fcr\u00fcn portf\u00f6y\u00fcne sahiptir.<\/p>\n<p>\u015eirket, sosyal sorumluluk ile hissedar de\u011ferini birlikte g\u00fc\u00e7lendiren kamu yarar\u0131na bir \u015firket olarak faaliyet g\u00f6stermektedir. Yakla\u015f\u0131k 1.305 \u00e7al\u0131\u015fan\u0131 ve Maryland, Kuzey Carolina, Quebec, Florida, Virginia ve New Hampshire&#8217;da tesisleri ile United Therapeutics, s\u00fcrd\u00fcr\u00fclebilir b\u00fcy\u00fcme i\u00e7in sa\u011flam bir operasyonel temel olu\u015fturmu\u015ftur.<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: United Therapeutics, ksenotransplantasyon (hayvan organlar\u0131 kullan\u0131m\u0131), allojenik resell\u00fclerizasyon ve otolog biyoyaz\u0131c\u0131 olmak \u00fczere \u00fc\u00e7 devrim niteli\u011finde teknolojiyle \u00fcretilmi\u015f organlar geli\u015ftiriyor. Temelde, hastalar\u0131n ihtiya\u00e7 duyduklar\u0131nda yedek organ sipari\u015f edebilece\u011fi d\u00fcnyan\u0131n ilk &#8220;organ eczanesini&#8221; yarat\u0131yorlar!<\/p>\n"},"faq":[{"question":"United Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \u015firketi ara\u015ft\u0131r\u0131n, limit emirleri kullanarak sipari\u015f verin ve yat\u0131r\u0131m\u0131n\u0131z\u0131 d\u00fczenli olarak izleyin."},{"question":"TETON 2 denemesinin sonu\u00e7lar\u0131 neden \u00f6nemli?","answer":"TETON 2 denemesi, idiopatik pulmoner fibrozis tedavisi i\u00e7in kritik bir klinik \u00e7al\u0131\u015fma olup, olumlu sonu\u00e7lar hisse fiyat\u0131nda \u00f6nemli art\u0131\u015flara yol a\u00e7abilir."},{"question":"United Therapeutics'in finansal durumu nas\u0131l?","answer":"\u015eirket g\u00fc\u00e7l\u00fc nakit ak\u0131\u015f\u0131na sahip olmakla birlikte, i\u015fletme giderlerinde art\u0131\u015f ya\u015fanm\u0131\u015ft\u0131r; bu durum marjlar \u00fczerinde bask\u0131 olu\u015fturabilir."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m \u00f6nerileri nelerdir?","answer":"Eyl\u00fcl kataliz\u00f6r\u00fcn\u00fc beklemek, k\u00fc\u00e7\u00fck kademeli al\u0131mlar yapmak, stop-loss emirleri belirlemek ve portf\u00f6y\u00fcn %5-10'unu a\u015fmamak \u00f6nerilir."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ve kullan\u0131c\u0131 dostu platformu ile yeni ba\u015flayanlar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"United Therapeutics hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesap do\u011frulamas\u0131n\u0131 tamamlay\u0131n, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \u015firketi ara\u015ft\u0131r\u0131n, limit emirleri kullanarak sipari\u015f verin ve yat\u0131r\u0131m\u0131n\u0131z\u0131 d\u00fczenli olarak izleyin."},{"question":"TETON 2 denemesinin sonu\u00e7lar\u0131 neden \u00f6nemli?","answer":"TETON 2 denemesi, idiopatik pulmoner fibrozis tedavisi i\u00e7in kritik bir klinik \u00e7al\u0131\u015fma olup, olumlu sonu\u00e7lar hisse fiyat\u0131nda \u00f6nemli art\u0131\u015flara yol a\u00e7abilir."},{"question":"United Therapeutics'in finansal durumu nas\u0131l?","answer":"\u015eirket g\u00fc\u00e7l\u00fc nakit ak\u0131\u015f\u0131na sahip olmakla birlikte, i\u015fletme giderlerinde art\u0131\u015f ya\u015fanm\u0131\u015ft\u0131r; bu durum marjlar \u00fczerinde bask\u0131 olu\u015fturabilir."},{"question":"Yeni ba\u015flayanlar i\u00e7in yat\u0131r\u0131m \u00f6nerileri nelerdir?","answer":"Eyl\u00fcl kataliz\u00f6r\u00fcn\u00fc beklemek, k\u00fc\u00e7\u00fck kademeli al\u0131mlar yapmak, stop-loss emirleri belirlemek ve portf\u00f6y\u00fcn %5-10'unu a\u015fmamak \u00f6nerilir."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7e\u015fitli para \u00e7ekme se\u00e7enekleri ve kullan\u0131c\u0131 dostu platformu ile yeni ba\u015flayanlar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-28T08:01:18+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-28T08:01:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\"},\"wordCount\":21,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\",\"name\":\"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"datePublished\":\"2025-08-28T08:01:18+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","og_locale":"tr_TR","og_type":"article","og_title":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-28T08:01:18+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-28T08:01:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"wordCount":21,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/","name":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r - United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","datePublished":"2025-08-28T08:01:18+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals4.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"United Therapeutics Corporation (UTHR) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; United Therapeutics Corporation (UTHR) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":353168,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu United Therapeutics Corporation (UTHR) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"},"pt_AA":{"locale":"pt_AA","id":353170,"slug":"how-to-buy-united-therapeutics-corporation","post_title":"Como comprar a\u00e7\u00f5es da United Therapeutics Corporation (UTHR) - Investimento em a\u00e7\u00f5es da United Therapeutics Corporation (UTHR)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-united-therapeutics-corporation\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/353169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=353169"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/353169\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334018"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=353169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=353169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=353169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}